Sugi Predict

Sugi Predict / Compounds / SCHEMBL969822

SCHEMBL969822

SCHEMBL969822

CCCCCCCC/C=C\CCCCCCCC(=O)C(OP(=O)(O)OCCN)(C(=O)CCCCCCC/C=C\CCCCCCCC)[C@@H](O)CO

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ P2RY10 O00398 7/20 0.44
▸ GPR34 Q9UPC5 3/20 0.44
▸ LPAR3 Q9UBY5 3/20 0.43
▸ LPAR1 Q92633 5/20 0.43
▸ ENPP2 Q13822 2/20 0.43
▸ LPAR4 Q99677 2/20 0.43
▸ LPAR5 Q9H1C0 2/20 0.43
▸ LPAR2 Q9HBW0 2/20 0.43
▸ CES2 O00748 1/20 0.43
▸ LPAR6 P43657 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.43
▸ S1PR1 P21453 1/20 0.42
▸ GPR174 Q9BXC1 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18262003 1.00 P2RY10 (0.44) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL7571747 1.00 P2RY10 (0.44) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL7570925 0.97 S1PR1 (0.47) P2RY10GPR34S1PR1
SCHEMBL5312425 0.94 ALDH1A1 (0.48) TRPV1S1PR1
SCHEMBL226745 0.94 PLA2G2C (0.43) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL17144721 0.94 PLA2G2C (0.43) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL3963403 0.94 PLA2G2C (0.43) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL19410782 0.94 PLA2G2C (0.43) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL37519 0.94 PLA2G2C (0.43) P2RY10GPR34LPAR3LPAR1ENPP2
SCHEMBL7573946 0.91 FABP3 (0.42) P2RY10GPR34LPAR3LPAR1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104670-A1 VARIANTS OF EPSTEIN-BARR VIRUS GLYCOPROTEIN B, NUCLEIC ACIDS ENCODING THE SAME, AND USES THEREOF SANOFI PASTEUR (FR) 2026-05-21 — — WO claimed
US-20250090650-A1 MODIFIED INFLUENZA B HEMAGGLUTININ POLYPEPTIDES AND NUCLEIC ACIDS AND USES THEREOF SANOFI (FR) 2025-03-20 — — US claimed
WO-2025051975-A1 MODIFIED INFLUENZA B HEMAGGLUTININ POLYPEPTIDES AND NUCLEIC ACIDS AND USES THEREOF SANOFI (FR) 2025-03-13 — — WO claimed
CN-117357479-A Marbofloxacin liposome and preparation method thereof 中国农业大学 2024-01-09 — — CN claimed
CN-115197080-A Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition 厦门赛诺邦格生物科技股份有限公司 2022-10-18 — — CN claimed
US-8765172-B2 Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids EPITARGET AS (NO) 2014-07-01 — — US claimed
WO-2026104670-A1 VARIANTS OF EPSTEIN-BARR VIRUS GLYCOPROTEIN B, NUCLEIC ACIDS ENCODING THE SAME, AND USES THEREOF SANOFI PASTEUR (FR) 2026-05-21 — — WO disclosed
US-12622922-B2 Compositions and methods for metal containing formulations capable of modulating immune response THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-05-12 — — US disclosed
WO-2025235506-A2 ATP7B-MODULATING COMPOSITIONS AND METHODS FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2025-11-13 — — WO disclosed
EP-4646427-A2 SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF DEM Biopharma, Inc. (US) 2025-11-12 — — EP disclosed
US-20250302767-A1 TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS USING NANO POLYMERS OF HISTONE DEACETYLASE INHIBITORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-10-02 — — US disclosed
EP-4601706-A1 REAGENTS AND METHODS FOR THE CONDITIONAL DELIVERY OF CARGO Massachusetts Institute of Technology (US) 2025-08-20 — — EP disclosed
WO-2025105824-A1 DISK-BASED MICROFLUIDIC PLATFORM FOR MANUFACTURING LIPID NANOPARTICLES USING CENTRIFUGAL FORCE AND METHOD USING SAME 고려대학교 산학협력단 2025-05-22 — — WO disclosed
WO-2002079447-A9 AVIAN LYSOZYME PROMOTER AVIGENICS INC (US) 2002-11-21 — — WO disclosed
WO-2002079447-A2 AVIAN LYSOZYME PROMOTER AVIGENICS, INC. (US) 2002-10-10 — — WO disclosed
EP-0845981-B1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES GENZYME CORP (US) 2002-09-25 — — EP disclosed
US-5935936-A A DRUG DELIVERY FOR GENE THERAPY COMPRISING A DIAMINO-POLY-ALKYLAMINE-CARBAMOYL CHOLESTEROL AND AT LEAST ONE PHOSPHATIDES GENZYME CORPORATION (US) 1999-08-10 — — US disclosed
EP-0845981-A1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES GENZYME CORPORATION (US) 1998-06-10 — — EP disclosed
WO-1997046223-A1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES GENZYME CORPORATION (US) 1997-12-11 — — WO disclosed
WO-1991007168-A1 RIBOFLAVIN AS A TANNING ENHANCER SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 1991-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622922-B2 Compositions and methods for metal containing formulations capable of modulating immune response STING1, CGAS, TLR3 P2RY10 236/4885GPR34 1056/4885LPAR3 611/4885
US-20250090650-A1 MODIFIED INFLUENZA B HEMAGGLUTININ POLYPEPTIDES AND NUCLEIC ACIDS AND USES THEREOF RNPEP, HNRNPAB, RNASEH1 P2RY10 3919/4885GPR34 4184/4885LPAR3 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.